Ligand Pharmaceuticals Reports Strong Q1 2026 Results, Reaffirms Full-Year Guidance
LGND has more than doubled off its 52-week low of $98.89.
Summary
Ligand Pharmaceuticals reported strong first-quarter 2026 financial results, with royalty revenue up 56% year-over-year and adjusted net income growing 30%, while reaffirming its full-year guidance.
Key Events · Earnings and Guidance · LGND
-
Strong First Quarter Financial Performance
Ligand Pharmaceuticals reported total revenues of $51.7 million for Q1 2026, a 14% increase year-over-year. Royalty revenue surged by 56% to $43.0 million, primarily driven by Filspari, Ohtuvayre, and Capvaxive. Adjusted net income grew 30% to $34.6 million, or $1.63 per diluted share, compared to $26.6 million, or $1.33 per diluted share, in Q1 2025.
-
Full-Year Guidance Reaffirmed
The company reaffirmed its 2026 full-year financial guidance, which was previously raised on April 27, 2026, following the announced acquisition of XOMA Royalty Corporation. This includes anticipated adjusted earnings per diluted share of $8.50 to $9.50 and total revenue of $270 million to $310 million.
-
Key Royalty Asset Milestones
The company highlighted the full FDA approval of Filspari for focal segmental glomerulosclerosis (FSGS) in April 2026, making it the first and only FDA-approved medicine for this rare kidney disease and its largest royalty contributor. Updates on other partner programs, including positive Phase 3 results for Qtorin rapamycin and Breakthrough Device Designation for AVIM Therapy, were also noted.
Analysis · LGND · Life Sciences
Ligand Pharmaceuticals delivered robust first-quarter results, driven by exceptional royalty revenue growth, and reaffirmed its previously raised full-year financial guidance. The significant increase in adjusted net income and royalty revenue indicates strong operational performance and successful execution of its royalty aggregation strategy. The reaffirmation of guidance, which incorporates the recent XOMA Royalty acquisition, provides confidence in the company's outlook and the integration of the new assets.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LGND was trading at $226.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $98.89 to $247.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.